LPCN News and Press, Lipocine Inc. From 08/05/21

Lipocine (NASDAQ:LPCN): Q2 GAAP EPS of -$0.08 misses by $0.03. As of June 30, 2021, the Company had $46.6 million of unrestricted cash, cash equivalents, and marketable investments, compared to $19.7 million of unrestricted cash, cash equivalents and marketable investment securities as of Dec...

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021 PR Newswire SALT LAKE CITY , Aug. 5, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today ...

NORTHBROOK, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- Clarus and Lipocine (NASDAQ: LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Clarus by Lipocine and to further resolve a patent interference between the parties. The action for patent infrin...

designer491/iStock via Getty Images Lipocine ([[LPCN]] -2.3%) has entered into a global settlement and license agreement with Clarus Therapeutics to resolve outstanding claims in an on-going intellectual property dispute. Terms of the settlement were not disclosed. Last month, Cantor Fitzgera...

Lipocine Announces Settlement With Clarus Therapeutics PR Newswire SALT LAKE CITY , July 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has en...

Lipocine To Present At The Ladenburg Thalmann Healthcare Conference PR Newswire SALT LAKE CITY , July 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announc...

syahrir maulana/iStock via Getty Images Cantor Fitzgerald has initiated shares of Lipocine (LPCN) with an overweight rating and a $3 price target (~121% upside). The firm says the company has "multiple shots on goal across its metabolic and endocrine disorders pipeline over the next 12-18 mon...

Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital Event PR Newswire SALT LAKE CITY , June 23, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine ...

Lipocine To Present At The Raymond James Human Health Innovation Conference PR Newswire SALT LAKE CITY , June 16, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, toda...

Lipocine (LPCN) jumps 9% premarket after announcing that the FDA has cleared its IND application to initiate a Phase 2 study to evaluate the therapeutic potential of LPCN 1154, an oral neuro-steroid product candidate, for the treatment of postpartum depression ((PPD)) in adults. A p...